Dr Rangan Chatterjee#1 Aging Expert: Dementia, Diabetes & Heart Disease Start After 40 When You Ignore This
CHAPTERS
Why “healthy aging” beats “anti-aging”: living longer vs living well
The conversation opens with the premise that most people accept decline as inevitable, even though vitality is a key life investment. Dr. Comite reframes the goal as pro-aging in excellent health—extending healthspan so the extra years are worth living.
Biological vs chronological age: decline starts becoming obvious after 40
Dr. Comite explains that chronological aging is unavoidable, but biological decline is optional to a degree if you intervene early. She cites data suggesting noticeable shifts around the 40s and again in the 60s, reinforcing the case for proactive action well before symptoms.
The biggest aging myth: “You can wait until you’re sick”
A central misconception is that normal-range tests and ‘watchful waiting’ are safe. Comite argues this is flawed because “normal” is often based on averages from a generally unhealthy population and misses early dysfunction.
Why chronic diseases are decades in the making (diabetes, heart disease, dementia)
They discuss how major chronic diseases build silently for years, often beginning with metabolic dysfunction long before diagnosis. The key problem is that traditional care typically responds only after damage accumulates.
“N=1 medicine”: the case for personalized health trajectories
Comite and Chatterjee align on treating the individual rather than population averages. They highlight seven “aging patterns” and introduce the value of simplifying overwhelm by focusing on a small set of high-impact markers.
The 5 key biomarkers of True Health (and why these five)
Comite lays out her core measurement framework: fasting glucose, HbA1c, fasting insulin, cholesterol risk ratio, and free testosterone. She explains these came from decades of endocrinology training and real-world clinical data tracking.
Fasting insulin: the early alarm bell for insulin resistance
They emphasize fasting insulin as a missing cornerstone in standard screening, especially in the UK. Comite argues insulin rises long before glucose or HbA1c cross diagnostic thresholds, and elevated insulin drives multiple aging diseases beyond diabetes.
Why trends matter: how often to test and why once-a-year is insufficient
Both argue that annual testing is too infrequent to connect lifestyle changes to outcomes. They advocate repeated measures (2–4x/year depending on risk) to reinforce behavior change and catch worsening trajectories early.
CGMs as a behavior-change tool: learning your personal glucose responses
They explore continuous glucose monitors (CGMs) as a way to see real-time cause-and-effect between food, sleep, alcohol, illness, and glucose fluctuations. Examples include carbs-first meals spiking glucose and alcohol contributing to nighttime crashes and insomnia.
Optimal targets for metabolic markers: what Comite aims for
Comite shares the ranges she considers optimal: fasting glucose around 70–80, HbA1c under 5, and fasting insulin ideally undetectable after fasting. They discuss how small increases in HbA1c correlate with higher long-term disease risk.
Testosterone redefined: a metabolic and brain-health hormone (men)
Chatterjee challenges the common view of testosterone as mainly about sex drive or aggression. Comite links low free testosterone to insulin resistance, visceral fat, cognition, mood/drive, and overall aging risk, and explains why free testosterone matters more than total.
HCG vs testosterone replacement: restoring signaling and preserving function
Comite describes using hCG as a first-line approach for many men to stimulate their own testosterone production (via LH-like activity). Dosage frequency, responsiveness over time, and individual variation determine whether hCG or testosterone therapy is used.
Risks and monitoring: polycythemia/erythrocytosis and safe ranges
They address concerns about hormone therapy and the need for careful monitoring. Comite highlights elevated red blood cell counts as a key risk when testosterone is too high for an individual, requiring dose adjustment or therapeutic phlebotomy/blood donation.
Women and testosterone (plus menopause hormones): overlooked drivers of healthspan
Comite argues testosterone is essential for women’s muscle, bone, cognition, and metabolic health, and declines starting in the 30s. She discusses how menopause is a hormonal ‘cliff’ for many women and why individualized estrogen, progesterone, and testosterone strategies matter—especially in perimenopause.
Scaling “health creation”: apps, virtual care, genetics, and the “who at 100?” question
They conclude by contrasting disease-management medicine with proactive health creation at scale using biomarkers, wearables, and virtual tools—analogous to modern banking apps. Comite emphasizes epigenetics (gene expression is modifiable) and ends with a motivating vision: decide who you want to be at 100 and build toward it now.
